Bristol-Myers Squibb Company vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored

Cost Efficiency in Pharmaceuticals: A Decade of Insights

__timestampBioMarin Pharmaceutical Inc.Bristol-Myers Squibb Company
Wednesday, January 1, 20141297640003932000000
Thursday, January 1, 20151520080003909000000
Friday, January 1, 20162096200004946000000
Sunday, January 1, 20172417860006066000000
Monday, January 1, 20183152640006547000000
Tuesday, January 1, 20193594660008078000000
Wednesday, January 1, 202052427200011773000000
Friday, January 1, 20214705150009940000000
Saturday, January 1, 202248366900010137000000
Sunday, January 1, 202357706500010693000000
Monday, January 1, 202458023500011949000000
Loading chart...

Igniting the spark of knowledge

Exploring Cost Efficiency in Pharmaceuticals: Bristol-Myers Squibb vs. BioMarin

In the competitive landscape of pharmaceuticals, cost efficiency is paramount. This analysis delves into the cost of revenue trends for Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc. from 2014 to 2023. Over this period, Bristol-Myers Squibb consistently outpaced BioMarin in cost of revenue, with figures peaking at approximately $10.7 billion in 2023, a staggering 1,750% higher than BioMarin's $577 million. Notably, Bristol-Myers Squibb's cost of revenue grew by 172% from 2014 to 2023, reflecting its expansive operations and market reach. In contrast, BioMarin's cost of revenue increased by 345%, indicating a significant scaling of its operations. This data underscores the differing scales and strategies of these two industry players, offering insights into their operational efficiencies and market strategies. As the pharmaceutical industry evolves, understanding these financial dynamics is crucial for stakeholders and investors alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025